1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
Real-time Estimate Tradegate  -  03:59 2022-08-08 pm EDT
60.48 EUR   +0.79%
07/26GERRESHEIMER : focuses on sustainable glass production
PU
07/18GERRESHEIMER AG : Notification and public disclosure of transactions by persons
EQ
07/14GERRESHEIMER AG : Gets a Buy rating from Credit Suisse
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution

05/09/2022 | 08:02am EDT


DGAP-Media / 09.05.2022 / 14:00

Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution

  • Partners are developing needle-free drug delivery platform for biologics and biosimilars
  • This Innovative solution improves patient?s quality of life, especially for people with chronic diseases
  • Partners will together expand their client base, product range and IP portfolio

Duesseldorf, Germany/Cambridge, Mass - May 9, 2022 ? Gerresheimer AG is expanding its portfolio of highly-innovative platform technologies for drug delivery. Gerresheimer, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, today announced an investment into US-based Portal Instruments, a developer of a next-generation needle-free drug delivery technology. Together, the partners aim at transforming the administration of injectable medicines and improving the patient?s experience, especially for those with chronic diseases.

Portal develops technology which allows for needle-free and high-speed subcutaneous injection of medicine and ? via connectivity ? the adherence monitoring along the treatment journey by patient and medical care provider. Portal Instruments is based in Cambridge, Massachusetts, and has its roots in MIT?s Bio Instrumentation Lab.

?Portal Instruments is developing groundbreaking technology. With our combined expertise in drug delivery innovations and manufacturing, we will contribute significantly to improving the patient?s quality of life as well as treatment efficiency and success. These results will also help to reduce costs to the healthcare system?, said Dietmar Siemssen, CEO of Gerresheimer. ?This investment is another milestone in our strategy process formula G. It will add to our capabilities to offer unique and innovative solutions to our clients. Together with Portal, we will further expand our client base as well as the existing IP and product portfolio?, he added.

?We are delighted to be working closer with Gerresheimer, who is a well-respected industry leader in drug delivery systems?, said Patrick Anquetil, CEO of Portal Instruments. ?As solutions provider and platform integrator, Gerresheimer has deep development and manufacturing know-how as well as a strong network of global pharma and biotech customers. This investment will support our scaling efforts. Gerresheimer?s financial backing will also accelerate Portal?s growth plans.? Gerresheimer acquired a minority stake and the agreement includes the option to increase the stake in the future. Gerresheimer will have a representative on Portal?s Board of Directors.

Portal?s needle-free injector and cartridge are components of a drug delivery platform for both biologics and biosimilars, completed and made available through biopharma partners. While many auto injectors on the market require patients to hold the needle onto their skin for 10 to 30 seconds, Portal's needle-free device can inject the same volume in less than a second. At the same time, this innovative type of injection helps to reduce pain during the application. And the injector is more than a drug delivery system: Thanks to its connectivity, adherence tracking, and customizable disease management becomes possible for both patient and medical care provider. Gerresheimer will support the development of the new technology, take part in manufacturing the reusable injector and supply cartridges containing the medicine.

Contact Press
Ueli Utzinger
Group Senior Director Marketing & Communication
T +49 211 6181-250
ueli.utzinger@gerresheimer.com

Contact Investor Relations
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

Contact Information Portal Instruments
Patrick Anquetil
Chief Executive Officer
T +1 617.500.4348
media@portalinstruments.com


About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

About Portal Instruments
Portal Instruments is a private medical device company focused on advanced drug delivery and backed by strategic and venture investors. Portal?s injector and cartridge are components of a drug delivery platform, completed and made available through biopharma partners. For more information, please visit www.portalinstruments.com or follow on LinkedIn
 



End of Media Release


Issuer: Gerresheimer AG
Key word(s): Enterprise

09.05.2022 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: carolin.nadilo@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1346507

 
End of News DGAP Media

1346507  09.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1346507&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about GERRESHEIMER AG
07/26GERRESHEIMER : focuses on sustainable glass production
PU
07/18GERRESHEIMER AG : Notification and public disclosure of transactions by persons
EQ
07/14GERRESHEIMER AG : Gets a Buy rating from Credit Suisse
MD
07/14GERRESHEIMER AG : Deutsche Bank gives a Buy rating
MD
07/14GERRESHEIMER AG : JP Morgan reiterates its Neutral rating
MD
07/13GERRESHEIMER AG : Buy rating from DZ Bank
MD
07/13GERRESHEIMER AG : Berenberg keeps its Buy rating
MD
07/13GERRESHEIMER : Presentation 2nd Quarter 2022
PU
07/13GERRESHEIMER AG : JP Morgan sticks Neutral
MD
07/13TRANSCRIPT : Gerresheimer AG, Q2 2022 Earnings Call, Jul 13, 2022
CI
More news
Analyst Recommendations on GERRESHEIMER AG
More recommendations
Financials
Sales 2022 1 713 M 1 751 M 1 751 M
Net income 2022 111 M 113 M 113 M
Net Debt 2022 1 070 M 1 094 M 1 094 M
P/E ratio 2022 17,1x
Yield 2022 2,22%
Capitalization 1 914 M 1 956 M 1 956 M
EV / Sales 2022 1,74x
EV / Sales 2023 1,61x
Nbr of Employees 10 803
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 60,00 €
Average target price 88,69 €
Spread / Average Target 47,8%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
GERRESHEIMER AG-29.16%1 913
ABBOTT LABORATORIES-22.37%191 321
MEDTRONIC PLC-9.83%123 942
BECTON, DICKINSON AND COMPANY3.44%72 505
HOYA CORPORATION-14.17%39 100
DEXCOM, INC.-33.63%34 975